Morgan Stanley maintains BridgeBio Oncology at Overweight, lowers price target to $12 from $13

Morgan Stanley kept its Overweight rating on BridgeBio Oncology but reduced its price target to $12 from $13, a 7.7% decrease. The new target suggests a 518.6% upside from the Nov 17 close of $1.94. Recent analyst price targets for the company range from $9 to $16.

Original reporting
Published Nov 18, 2026, 2:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains BridgeBio Oncology at Overweight, lowers price target to $12 from $13 — source image
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

A lower price target can influence near-term sentiment and positioning, but without new company fundamentals (earnings, trial results, approvals) the impact is likely incremental.

02

Market read

Traders may update expectations for BBIO’s valuation, but the lack of new operational or clinical catalysts limits urgency.

03

What to watch

The article does not include the underlying thesis for the PT change, so traders may discount the move until more detail is available in the full note.

Relevance 4/10Novelty 4/10Timing: analyst note update, no scheduled catalyst mentioned

Background

The piece summarizes Morgan Stanley’s latest rating and price-target adjustment for BridgeBio Oncology and notes a recent range of other analysts’ targets.

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

Morgan Stanley maintained BridgeBio Oncology at Overweight and cut its price target to $12 from $13, signaling a valuation reset.

Expected impact

Likely mild downward pressure or limited upside as traders adjust expectations to the lower target while the Overweight stance remains supportive.

Evidence & confidence

The article provides a specific analyst price-target reduction (from $13 to $12) while keeping the rating at Overweight, implying reduced upside rather than a downgrade.

Market effects

Limited read-through for biotech/oncology peers since this is a single-name analyst target change without new clinical or regulatory data.

No direct regional market linkage indicated.

Primarily company-specific sentiment, not a cross-market driver.

Counterpoint

The unchanged Overweight rating could still support dip-buying, making the PT cut less important than the maintained stance.

Key entities

  • BridgeBio Oncology

    Subject of the analyst action summarized in the article.

  • Morgan Stanley

    Maintained Overweight and lowered the price target to $12 from $13.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.